Companies Inari Medical, Inc.
Inari Medical CEO salary & total pay, FY2023: $5.1M
Inari Medical (INRI) CEO salary, fiscal 2023: Andrew Hykes was paid a salary of $700,000 and $5,083,365 in total compensation. Free brief. Every figure links to the company’s own filing.
Inari Medical, Inc. no longer files a proxy statement; its last pay data is FY2023.
Andrew Hykes's complete compensation dossier
A PDF and a CSV sent to your email: Andrew Hykes's pay in every fiscal year Inari Medical, Inc. reported it, line by line, with Andrew Hykes's equity grants and Inari Medical, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $5,083,365FY2023
CEO total pay was $5,083,365 in fiscal 2023; the brief holds no earlier figure for this CEO.
FY2023: salary $700,000 · bonus $0 · stock awards $2,606,744 · option awards $937,488
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Hykes | $700,000 | $0 | $2,606,744 | $937,488 | $826,000 | $0 | $13,133 | $5,083,365 |
| Chief Executive Officer | ||||||||
| Thomas Tu | 497,500 | 0 | 1,199,072 | 431,242 | 354,000 | 0 | 14,133 | 2,495,947 |
| Chief Medical Officer | ||||||||
| Mitchell Hill | 497,500 | 0 | 1,199,072 | 431,242 | 354,000 | 0 | 13,133 | 2,494,947 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Andrew Hykes | $5,083,365 | $3,127,714 | $2,563,026 | ↑ +1,955,651 |
| Thomas Tu | 2,495,947 | 2,323,492 | 1,960,794 | ↑ +172,455 |
| Mitchell Hill | 2,494,947 | 2,321,629 | 1,895,921 | ↑ +173,318 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation programs are designed to align the interests of our executives with business priorities and stockholders, attract, retain, engage, and motivate talented executive officers, and remain market competitive and internally equitable.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mitchell Hill | RSU | 2023-02-18 | — | — | 21,412 | — | $1,199,072 |
| Thomas Tu | RSU | 2023-02-18 | — | — | 21,412 | — | 1,199,072 |
| Thomas Tu | OPTION | 2023-02-18 | — | — | 16,599 | — | 431,242 |
| Andrew Hykes | OPTION | 2023-02-18 | — | — | 36,085 | — | 937,488 |
| Andrew Hykes | RSU | 2023-02-18 | — | — | 46,549 | — | 2,606,744 |
| Mitchell Hill | OPTION | 2023-02-18 | — | — | 16,599 | — | 431,242 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mitchell Hill | $1,199,072 | $0 | $431,242 | 0.0% |
| Thomas Tu | 1,199,072 | 0 | 431,242 | 0.0% |
| Andrew Hykes | 2,606,744 | 0 | 937,488 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Andrew Hykes | RSU | — | 4,008 | — | $260,199 |
| Andrew Hykes | RSU | — | 14,940 | — | 969,905 |
| Andrew Hykes | Option | 9,021 | 27,063 | 56 | — |
| Andrew Hykes | RSU | — | 34,912 | — | 2,266,487 |
| Andrew Hykes | Option | 161,100 | — | 0.43 | — |
| Andrew Hykes | Option | 16,719 | — | 0.46 | — |
| Andrew Hykes | Option | 16,719 | — | 6.45 | — |
| Mitchell Hill | RSU | — | 2,673 | — | 173,531 |
| Mitchell Hill | RSU | — | 9,968 | — | 647,123 |
| Mitchell Hill | Option | 4,149 | 12,450 | 56 | — |
| Mitchell Hill | RSU | — | 16,059 | — | 1,042,550 |
| Mitchell Hill | Option | 94,477 | — | 0.46 | — |
| Thomas Tu | RSU | — | 2,673 | — | 173,531 |
| Thomas Tu | RSU | — | 9,968 | — | 647,123 |
| Thomas Tu | Option | — | 12,450 | 56 | — |
| Thomas Tu | RSU | — | 16,059 | — | 1,042,550 |
| Thomas Tu | Option | 139,584 | — | 0.46 | — |
| Thomas Tu | Option | 4,149 | — | 6.45 | — |
| Thomas Tu | Option | 8,420 | — | 0 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Donald MilderIndependent · Board Chair · Compensation | $105,500 | $160,968 | — | — | — | $266,428 |
| Cynthia LuccheseIndependent · Audit · Nominating/Governance · Risk | 75,000 | 160,928 | — | — | — | 235,928 |
| Jonathan Root, M.DIndependent · Compensation · Nominating/Governance | 70,000 | 160,968 | — | — | — | 230,928 |
| Kirk NielsenIndependent · Compensation · Nominating/Governance · Not standing for re-election | 66,134 | 160,968 | — | — | — | 227,062 |
| Rebecca ChambersIndependent · Audit · Nominating/Governance · Compensation | 60,000 | 160,928 | — | — | — | 220,928 |
| Robert WarnerIndependent · Audit · Nominating/Governance · Compensation | 60,000 | 160,968 | — | — | — | 220,928 |
| Catherine SzymanIndependent · Compensation | 59,544 | 160,968 | — | — | — | 220,472 |
| Dana G. Mead JrIndependent · Compensation | 57,500 | 160,968 | — | — | — | 218,428 |
| William HoffmanNot independent · Nominating/Governance | 37,500 | 160,928 | — | — | — | 198,428 |
| Andrew HykesEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $160,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $591,178 |
| Equity awards (grant-date value) | $1,448,592 |
| All other compensation | $0 |
| Total cost of the board | $2,039,770 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Inari Medical as a peer
Companies that benchmark against INRI
3 companies name INRI as a compensation peer
- 10x Genomics, Inc.TXGFY2025
- ACCURAY INCARAYFY2026
- Alphatec Holdings, Inc.ATECFY2025
- ANGIODYNAMICS INCANGOFY2026
- ESTABLISHMENT LABS HOLDINGS INC.ESTAFY2025
- Inogen IncINGNFY2025
- Orthofix Medical Inc.OFIXFY2025
- PROCEPT BioRobotics CorpPRCTFY2025
- RxSight, Inc.RXSTFY2025
- STAAR SURGICAL COSTAAFY2025
- TransMedics Group, Inc.TMDXFY2025
- TREACE MEDICAL CONCEPTS, INC.TMCIFY2025
- Vericel CorpVCELFY2025
Each company listed discloses INRI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INRI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Inari Medical, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Silk Road Medical | 2023 | Chas McKhann | $105,871 | $13,123,059 | $0 | $93,275 | $13,423,834 |
| 2 | NovoCure | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 3 | Abiomed | 2022 | Michael Minogue | 788,631 | 6,557,724 | 3,072,561 | 2,237,836 | 12,665,992 |
| 4 | Glaukos | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 5 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 6 | iRhythm Technologies | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 7 | AtriCure | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | ShockWave Medical | 2022 | Doug Godshall | 644,231 | 6,845,660 | 0 | 923,650 | 8,418,871 |
| 9 | LivaNova | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 10 | Inspire Medical Systems | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 11 | Staar Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 12 | Artivion | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 13 | Tandem Diabetes Care | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 14 | AngioDynamics | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 15 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 16 | Penumbra | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
| — | Cardiovascular Systems | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Inari Medical, Inc. | not disclosed | RSU 75 · Option 25 | not disclosed | FW Cook |
| Abiomed | not disclosed | PSU 50 · RSU 30 · Option 20 | not disclosed | Willis Towers Watson |
| AngioDynamics | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Artivion | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure | not disclosed | PSU 50 · Restricted Stock 50 | No | Korn Ferry |
| Cardiovascular Systems | not disclosed | not disclosed | not disclosed | not disclosed |
| Glaukos | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inspire Medical Systems | 111.4% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Technologies | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LivaNova | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Nevro | 53.7% | RSU 50 · PSU 50 | No | Aon |
| NovoCure | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| Penumbra | not disclosed | not disclosed | No | Compensia |
| ShockWave Medical | 142.1% | RSU 50 · PRSU 50 | No | Compensia |
| Silk Road Medical | 86.1% | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
| Staar Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tandem Diabetes Care | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-04-24 | 44,404,487 | 2,164,720 | 546,058 | 95.35% | Passed |
| 2023 | 2023-05-18 | 42,519,009 | 3,417,294 | 111,003 | 92.56% | Passed |
| 2022 | 2022-05-26 | 36,070,016 | 5,283,156 | 115,997 | 87.22% | Passed |
| 2021 | 2021-05-27 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-04-24 | 95.35%a |
| 2023 | 2023-05-18 | 92.56%b |
| 2022 | 2022-05-26 | 87.22%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be considered votes cast on Proposal No. 3 and will have no effect on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be considered votes cast on Proposal No. 3, and thus will have no effect on this proposal.”.
c. Approved under the standard stated in the filing — “The approval by the holders of a majority in voting power of the votes cast affirmatively (excluding abstentions and broker non votes), or "Majority Cast," is required with regard to the ratification of the selection of our independent registered public accounting firm, approval on an advisory basis, of the compensation of our named executive officers, and the approval, on an advisory basis, on the frequency of future non-binding votes on the compensation our named executive officers.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas Tu | Chief Medical Officer | 2025-01-01 | D | 699 | $51 | $35,684 | Common | Form 4 ↗ |
| William Hoffman | Director | 2025-01-01 | D | 1,533 | 51 | 78,260 | Common | Form 4 ↗ |
| William Hoffman | Director | 2025-01-01 | D | 713 | 51 | 36,399 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-01-01 | D | 516 | 51 | 26,342 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-01-01 | D | 751 | 51 | 38,339 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 146 | 51 | 7,453 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-01-01 | D | 337 | 51 | 17,204 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 227 | 51 | 11,588 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 176 | 51 | 8,985 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 63 | 51 | 3,216 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-01-01 | D | 1,319 | 51 | 67,335 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-01-01 | D | 509 | 51 | 25,984 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 276 | 51 | 14,090 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-01-01 | D | 949 | 51 | 48,446 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-01-01 | D | 1,632 | 51 | 83,314 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-01-01 | D | 149 | 51 | 7,606 | Common | Form 4 ↗ |
| William Hoffman | Director | 2025-01-06 | D | 58,925 | 61 | 3,610,335 | Common | Form 4 ↗ |
| William Hoffman | Director | 2025-01-06 | D | 141,075 | 60 | 8,482,840 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-04 | A | 67,282 | 0 | 0 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-04 | A | 21,102 | 0 | 0 | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-02-04 | A | 21,102 | 0 | 0 | Common | Form 4 ↗ |
| Karen Silva | Principal Accounting Officer | 2025-02-04 | A | 5,504 | 0 | 0 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-10 | D | 8,420 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-10 | D | 139,584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-10 | A | 8,420 | 6 | 54,348 | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-10 | A | 139,584 | 0 | 63,776 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | D | 16,719 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | D | 161,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | A | 16,719 | 6 | 107,914 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | A | 161,100 | 0 | 69,015 | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | D | 16,719 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-10 | A | 16,719 | 0 | 7,639 | Common | Form 4 ↗ |
| Catherine Szyman | Director | 2025-02-19 | D | 22,429 | — | — | Common | Form 4 ↗ |
| Cynthia Lucchese | Director | 2025-02-19 | D | 38,429 | — | — | Common | Form 4 ↗ |
| Donald Milder | Director | 2025-02-19 | D | 259,126 | — | — | Common | Form 4 ↗ |
| Dana G. Mead Jr | Director | 2025-02-19 | D | 11,148 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 717,637 | — | — | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-19 | A | 7,406 | — | — | Common | Form 4 ↗ |
| Rebecca Chambers | Director | 2025-02-19 | D | 9,684 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 44,693 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | A | 20,393 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 1,000 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 1,550 | — | — | Common | Form 4 ↗ |
| Cynthia Lucchese | Director | 2025-02-19 | D | 49,719 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 1,550 | — | — | Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-02-19 | D | 5,293 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-02-19 | D | 11,761 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin T. Strange | Chief Financial Officer | 2025-02-19 | D | 67,502 | — | — | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-19 | D | 16,231 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catherine Szyman | Director | 2025-02-19 | D | 49,719 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan D. Root | Director | 2025-02-19 | D | 335 | — | — | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-19 | D | 16,599 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan D. Root | Director | 2025-02-19 | D | 541,149 | — | — | Common | Form 4 ↗ |
| Donald Milder | Director | 2025-02-19 | D | 2,831,714 | — | — | Common | Form 4 ↗ |
| Robert Warner | Director | 2025-02-19 | D | 12,149 | — | — | Common | Form 4 ↗ |
| Thomas Tu | Chief Medical Officer | 2025-02-19 | D | 478,767 | — | — | Common | Form 4 ↗ |
| Karen Silva | Principal Accounting Officer | 2025-02-19 | D | 14,719 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 36,085 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Hoffman | Director | 2025-02-19 | D | 238,987 | — | — | Common | Form 4 ↗ |
| Andrew Hykes | Director | 2025-02-19 | D | 1,550 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (104 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Andrew Hykes. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 5,083,365. View filing ↗
- Section 01, Thomas Tu. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 2,495,947. View filing ↗
- Section 01, Mitchell Hill. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 2,494,947. View filing ↗
- Section 03, Mitchell Hill RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Tu RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Tu OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Hykes OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Hykes RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mitchell Hill OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 08, Donald Milder. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 266,428. View filing ↗
- Section 08, Cynthia Lucchese. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 235,928. View filing ↗
- Section 08, Jonathan Root, M.D. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 230,928. View filing ↗
- Section 08, Kirk Nielsen. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 227,062. View filing ↗
- Section 08, Rebecca Chambers. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,928. View filing ↗
- Section 08, Robert Warner. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,928. View filing ↗
- Section 08, Catherine Szyman. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,472. View filing ↗
- Section 08, Dana G. Mead Jr. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 218,428. View filing ↗
- Section 08, William Hoffman. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 198,428. View filing ↗
- Section 08, Andrew Hykes. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Hoffman 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Hoffman 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Hoffman 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Hoffman 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Silva 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Szyman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Lucchese 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald Milder 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dana G. Mead Jr 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rebecca Chambers 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Lucchese 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine Szyman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan D. Root 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan D. Root 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald Milder 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Warner 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Silva 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Hoffman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-04-25. Item 5.07 · say-on-pay result. As reported: 95.35% (votes for as printed: 44,404,487). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-19. Item 5.07 · say-on-pay result. As reported: 92.56% (votes for as printed: 42,519,009). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-27. Item 5.07 · say-on-pay result. As reported: 87.22% (votes for as printed: 36,070,016). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 591,178 + equity 1,448,592 + all other 0 = 2,039,770, summed across the director compensation table rows.
- Silk Road Medical, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. View filing ↗
- NovoCure, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in NovoCure's own proxy. As printed: 13,198,354. View filing ↗
- Abiomed, Section 10b CEO total. DEF 14A, filed 2022-06-28. CEO total compensation as printed in Abiomed's own proxy. As printed: 12,665,992. View filing ↗
- Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
- Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
- iRhythm Technologies, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. View filing ↗
- AtriCure, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. View filing ↗
- ShockWave Medical, Section 10b CEO total. DEF 14A, filed 2023-04-21. CEO total compensation as printed in ShockWave Medical's own proxy. As printed: 8,418,871. View filing ↗
- LivaNova, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova's own proxy. As printed: 8,047,217. View filing ↗
- Inspire Medical Systems, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems's own proxy. As printed: 7,711,784. View filing ↗
- Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
- Artivion, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion's own proxy. As printed: 6,883,108. View filing ↗
- Tandem Diabetes Care, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. View filing ↗
- AngioDynamics, Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics's own proxy. As printed: 6,060,145. View filing ↗
- Inari Medical, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2024-03-13. CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. View filing ↗
- Penumbra, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra's own proxy. As printed: 851,621. View filing ↗
- Section 10a, AngioDynamics reciprocity. DEF 14A. AngioDynamics names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ShockWave Medical reciprocity. DEF 14A. ShockWave Medical names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, STAAR Surgical Company reciprocity. DEF 14A. STAAR Surgical Company names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗